Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial

Key Points

• Five-year survival rates reached 50% in melanoma patients treated with ipilimumab and nivolumab together.
• Biomarker analysis revealed significant associations that could help predict treatment responses.
• Phase 2 trial assessed the effects of dual immune checkpoint inhibitors on long-term survival rates.
• These findings highlight the potential for tailored therapies in improving outcomes for melanoma patients.